MENU
+Compare
SKYE
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$4.11
Change
-$0.14 (-3.29%)
Capitalization
128.62M

SKYE Skye Bioscience Forecast, Technical & Fundamental Analysis

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California... Show more

SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for SKYE with price predictions
Jun 27, 2025

SKYE's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for SKYE turned positive on June 23, 2025. Looking at past instances where SKYE's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 20, 2025. You may want to consider a long position or call options on SKYE as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where SKYE advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 84 cases where SKYE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

SKYE broke above its upper Bollinger Band on June 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SKYE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.149) is normal, around the industry mean (16.366). P/E Ratio (3.566) is within average values for comparable stocks, (58.189). SKYE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.247).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKYE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AELTF1.10N/A
N/A
Adacel Technologies Ltd.
FOCIF2.50N/A
N/A
Focusrite Plc.
GSFD0.12N/A
N/A
Global Seafood Technologies, Inc.
HPHTF11.46N/A
N/A
Hamamatsu Photonics
TERRF9.95N/A
N/A
Terna Rete Elettrica Nazionale SPA

SKYE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with CRBP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then CRBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
-3.29%
CRBP - SKYE
46%
Loosely correlated
-7.73%
JANX - SKYE
41%
Loosely correlated
-1.57%
OVID - SKYE
36%
Loosely correlated
-11.95%
VKTX - SKYE
34%
Loosely correlated
-5.86%
ARWR - SKYE
33%
Loosely correlated
+0.06%
More